Characterization of MMP-3 from Rheumatoid Arthritis Patients and the Production of Rabbit Polyclonal Anti-MMP-3 Antibody

Authors

  • Sulistiana Prabowo Faculty of Medicine, Hang Tuah University, Surabaya, Indonesia.
  • Sartono Sartono Faculty of Medicine, Hang Tuah University, Surabaya, Indonesia.
  • Irmawati Dikman Faculty of Medicine, Hang Tuah University, Surabaya, Indonesia.
  • Fitri Handajani Faculty of Medicine, Hang Tuah University, Surabaya, Indonesia.
  • Aulanni Aulanni Faculty of Veterinery Medicine, Brawijaya University, Malang, Indonesia.

Keywords:

MMP-3, rheumatoid arthritis, antibody, rabbit.

Abstract

Rheumatoid arthritis (RA) is a chronic, systemic disorder characterised by inflammation of the joint synovial membrane associated with cytokine release resulted in progressive joint destruction. RA pathogenesis was thought to be initiated by bone resorption by osteoclasts, immune system activation and matrix metalloproteinase (MMP) production. Serum MMP-3 levels at the onset of disease is predictive of joint damage progression and thought to play an important role in joint destruction in RA. This study aimed to determine the presence of elevated serum MMP-3 in RA patients and to produce custom made patient derived anti-MMP-3 antibody for diagnostic and prognostic purposes. We found significant increase of serum MMP-3 in RA patients participated in this study and able to produce anti-MMP-3 antibody from their serum. The success of MMP-3 antibody production from RA patients in this study is novel and will be beneficial for future diagnostic and prognostic purposes for patients from similar geographical area. Currently none of the MMP-3 antibodies which are available commercially were produced in the Asian countries which raised questions about their specificity for the local use.

References

. Mamehara A, Sugimoto T, Sugiyama D, Morinobu S, Tsuji G, Kawano S, et al. Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs. Kobe J Med Sci.56(3):E98-107.2010.

. Kaito T, Ohshima S, Fujiwara H, Makino T, Yonenobu K. Predictors for the progression of cervical lesion in rheumatoid arthritis under the treatment of biological agents. Spine (Phila Pa 1976). 38(26):2258-63. 2013.

. Hiura K, Iwaki-Egawa S, Kawashima T, Fujisawa S, Takeda T, Komori H, et al. The diagnostic utility of matrix metalloproteinase-3 and high-sensitivity C-reactive protein for predicting rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-negative patients with recent-onset undifferentiated arthritis. Rheumatol Int. 33(9):2309-14. 2013.

. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum. 43(4):852-8. 2000.

. Okada Y, Naka K, Kawamura K, Matsumoto T, Nakanishi I, Fujimoto N, et al. Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase = gelatinase B) in osteoclasts: implications for bone resorption. Lab Invest. 72(3):311-22. 1995.

. Ma JD, Zhou JJ, Zheng DH, Chen LF, Mo YQ, Wei XN, et al. Serum matrix metalloproteinase-3 as a noninvasive biomarker of histological synovitis for diagnosis of rheumatoid arthritis. Mediators Inflamm. 2014:179284. 2014.

. Tchetverikov I, Lard LR, DeGroot J, Verzijl N, TeKoppele JM, Breedveld FC, et al. Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis. 62(11):1094-9. 2003.

. Green MJ, Gough AK, Devlin J, Smith J, Astin P, Taylor D, et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford). 42(1):83-8. 2003.

. Tetlow LC, Woolley DE. The effects of 1 alpha,25-dihydroxyvitamin D(3) on matrix metalloproteinase and prostaglandin E(2) production by cells of the rheumatoid lesion. Arthritis Res. 1(1):63-70. 1999.

. Galil SM, El-Shafey AM, Hagrass HA, Fawzy F, Sammak AE. Baseline serum level of matrix metalloproteinase-3 as a biomarker of progressive joint damage in rheumatoid arthritis patients. Int J Rheum Dis. 19(4):377-84. 2016.

. Lohmander LS, Brandt KD, Mazzuca SA, Katz BP, Larsson S, Struglics A, et al. Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritis. Arthritis Rheum. 52(10):3160-7. 2005.

. Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis. J Rheumatol. 29(5):883-9. 2002.

. Taylor DJ, Cheung NT, Dawes PT. Increased serum proMMP-3 in inflammatory arthritides: a potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis.53(11):768-72.1994.

. Urata Y, Uesato R, Tanaka D, Nakamura Y, Motomura S. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study. Ann Rheum Dis. 71(4):534-40. 2012.

. Sun S, Bay-Jensen AC, Karsdal MA, Siebuhr AS, Zheng Q, Maksymowych WP, et al. The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases. BMC Musculoskelet Disord. 2012;15:93. 2012.

. Ma JD, Wei XN, Zheng DH, Mo YQ, Chen LF, Zhang X, et al. Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study. Arthritis Res Ther. 17:289. 2015.

. Nagashima T, Minota S. Caution is needed when interpreting changes of matrix metalloproteinase-3 in patients with rheumatoid arthritis. Rheumatol Int. 34(7):1025-6. 2014.

. Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis.61(2):161-6.2002.

. Murphy G, Cockett MI, Stephens PE, Smith BJ, Docherty AJ. Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J. 248(1):265-8. 1987.

. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem. 267(6):3581-4. 1992.

. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 4(2):197-250. 1993.

. Wu JJ, Lark MW, Chun LE, Eyre DR. Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage. J Biol Chem. 266(9):5625-8. 1991.

. Flannery CR, Lark MW, Sandy JD. Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage. J Biol Chem. 267(2):1008-14. 1992.

. Maksymowych WP, Landewe R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum. 56(6):1846-53. 2007.

. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 115(Pt 19):3719-27. 2002.

. Cawston TE, Mercer E. Preferential binding of collagenase to alpha 2-macroglobulin in the presence of the tissue inhibitor of metalloproteinases. FEBS Lett. 1986;209(1):9-12.

. Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem. 264(20):11539-42. 1989.

. Chen JJ, Huang JF, Du WX, Tong PJ. Expression and significance of MMP3 in synovium of knee joint at different stage in osteoarthritis patients. Asian Pac J Trop Med. 7(4):297-300. 2014.

Downloads

Published

2017-05-16

How to Cite

Prabowo, S., Sartono, S., Dikman, I., Handajani, F., & Aulanni, A. (2017). Characterization of MMP-3 from Rheumatoid Arthritis Patients and the Production of Rabbit Polyclonal Anti-MMP-3 Antibody. International Journal of Sciences: Basic and Applied Research (IJSBAR), 33(2), 108–119. Retrieved from https://www.gssrr.org/index.php/JournalOfBasicAndApplied/article/view/6750

Issue

Vol. 33 No. 2 (2017)

Section

Articles

License

Authors who submit papers with this journal agree to the following terms.